SCHEMBL366649

SCHEMBL366649

COc1cc(CBr)ccc1C(=O)NS(C)(=O)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB3 P13945 6/20 0.50
ADRB1 P08588 3/20 0.50
FLT1 P17948 1/20 0.47
FLT4 P35916 1/20 0.47
KDR P35968 1/20 0.47
SCN9A Q15858 2/20 0.42
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
TP53 P04637 1/20 0.40
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPC1 O15118 1/20 0.40
ALOX5 P09917 1/20 0.40
OR51E2 Q9H255 1/20 0.40
HDAC11 Q96DB2 1/20 0.39
NR1H4 Q96RI1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30854413 0.83 ADRB3 (0.53) ADRB3ADRB1FLT1FLT4KDR
SCHEMBL10235812 0.81 MCL1 (0.49) ADRB3ADRB1SCN9AALDH1A1
SCHEMBL22091934 0.81 GPR27 (0.53) ADRB3ADRB1FLT1FLT4KDR
SCHEMBL22108591 0.80 ADRB3 (0.50) ADRB3ADRB1FLT1FLT4KDR
SCHEMBL28741592 0.80 ADRB3 (0.50) ADRB3ADRB1FLT1FLT4KDR
SCHEMBL366008 0.80 FLT1 (0.51) ADRB3ADRB1FLT1FLT4KDR
SCHEMBL2772618 0.79 HTT (0.48) ALDH1A1MAPTHPGDPPARGPPARA
SCHEMBL2476590 0.79 NR1H4 (0.45) ALDH1A1MAPTHPGDPPARGPPARA
SCHEMBL22444616 0.79 ADRB3 (0.49) ADRB3ADRB1FLT1FLT4KDR
SCHEMBL366513 0.79 PTGER4 (0.47) ADRB3ADRB1FLT1FLT4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9102621-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-11 US disclosed
US-9102621-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-11 US disclosed
US-9102621-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-11 US disclosed
EP-2593431-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-19 EP disclosed
EP-2593431-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-19 EP disclosed
EP-2593431-A2 CHEMICAL COMPOUNDS Pfizer Limited (GB) 2013-05-22 EP disclosed
US-20130109708-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
US-20130109708-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
US-20130109708-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012007869-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109708-A1 Chemical Compounds SCN1A, SCN1B, SCN7A ADRB3 2301/4885ADRB1 1413/4885FLT1 3351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.